2Q'25 vs. 2Q'24: EBITDA: $ 1.860 Bn (-0.1% vs. +0.3% BS(e) and -0.6% consensus); BDI: $ 1.793 Bn (+255.8% vs. +65.1% BS(e) and +60.9% consensus); 1H'25 vs. 1H'24: EBITDA: $ 3.440 Bn (-9.9% vs. -9.7% BS(e) and -10.2% consensus); BDI: $ 2.598 Bn (+80.2% vs. +13.5% BS(e) and +12.1% consensus).
Rdos. 2T'25 vs 2T'24: EBITDA: 1.860 M euros (-0,1% vs +0,3% BS(e) y -0,6% consenso); BDI: 1.793 M euros (+255,8% vs +65,1% BS(e) y +60,9% consenso); Rdos. 1S'25 vs 1S'24: EBITDA: 3.440 M euros (-9,9% vs -9,7% BS(e) y -10,2% consenso); BDI: 2.598 M euros (+80,2% vs +13,5% BS(e) y +12,1% consenso).
NEWS SUMMARY: ARCELOR MITTAL, ELECTRICITY SECTOR, FLUIDRA, MELIA, MERLIN PROPERTIES, NEINOR HOMES, REDEIA, VISCOFAN. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 2Q’25 results to be released over the coming days in Spain. Growth resisting for now European stock markets ended with slight gains in view of the signs of resistance in the 2Q’25 GDP and ahead of the Fed meeting, w...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ARCELOR MITTAL, FLUIDRA, MELIA, MERLIN PROPERTIES, NEINOR HOMES, REDEIA, SECTOR ELÉCTRICO, VISCOFAN. EUROPA: AB INBEV, AIRBUS, BMW, ING GROEP, SANOFI, SAFRAN, SOCIETE GENERALE, VINCI. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 2T’25 que se publicarán en España y Europa en los próximos días. El crecimien...
2Q'25 vs. 2Q'24 Results Sales: € 906.35 M (-2.1% vs. -1.7% BS(e)); EBITDA: € 57.4 M (+51.1% vs. +7.7% BS(e)); EBIT: € 27.45 M (+85.5% vs. +48.1% BS(e)); Net Profit: € -7.85 M (€ -29.5 M in 1H'24 vs. € -8.04 M BS(e)); 1H'25 vs. 1H'24 Results Sales: € 1.689 Bn (-1.8% vs. -1.6% BS(e)); EBITDA: € 84.1 M (+46.3% vs. +17.6% BS(e)); EBIT: € 46.25 M (+139.6% vs. +111.0% BS(e)); Net Profit: € -29.65 M (€ -34.2 M in 1H'24 vs. € -29.84 M BS(e));
Rdos. 2T'25 vs 2T'24: Ventas: 906,35 M euros (-2,1% vs -1,7% BS(e); EBITDA: 57,4 M euros (+51,1% vs +7,7% BS(e)); EBIT: 27,45 M euros (+85,5% vs +48,1% BS(e)); BDI: -7,85 M euros (-29,5 M euros en 1S'24 vs -8,04 M euros BS(e)); Rdos. 1S'25 vs 1S'24: Ventas: 1.689 M euros (-1,8% vs -1,6% BS(e)); EBITDA: 84,1 M euros (+46,3% vs +17,6% BS(e)); EBIT: 46,25 M euros (+139,6% vs +111,0% BS(e)); BDI: -29,65 M euros (-34,2 M euros en 1S'24 vs -29,84 M euros BS(e)).
2Q'25 vs. 2Q'24 Results EBITDA: € 1.28 Bn (-4.0% vs. -5.2% BS(e) and -2.4% consensus); Net Profit: € 458.0 M (-9.8% vs. -12.8% BS(e) and -7.5% consensus); 1H'25 vs. 1H'24 Results EBITDA: € 2.711 Bn (+12.3% vs. +11.7% BS(e) and +13.3% consensus); Net Profit: € 1.041 Bn (+30.1% vs. +27.6% BS(e) and +31.0% consensus);
Rdos. 2T'25 vs 2T'24: EBITDA: 1.280 M euros (-4,0% vs -5,2% BS(e) y -2,4% consenso); BDI: 458,0 M euros (-9,8% vs -12,8% BS(e) y -7,5% consenso); Rdos. 1S'25 vs 1S'24: EBITDA: 2.711 M euros (+12,3% vs +11,7% BS(e) y +13,3% consenso); BDI: 1.041 M euros (+30,1% vs +27,6% BS(e) y +31,0% consenso);
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACCIONA, ACCIONA ENERGÍA, CAF, ENDESA, IBERDROLA, UNICAJA. EUROPA: AIR LIQUIDE, ESSILORLUXOTTICA, PHILIPS. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 2T’25 que se publicarán en España y Europa en los próximos días. Tras el acuerdo… Europa termina en pérdidas La digestión del acuerdo comercial fue apagan...
NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, CAF, ENDESA, IBERDROLA, UNICAJA. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 2Q’25 results to be released over the coming days in Spain. After the agreement... losses in Europe With the digestions of the trade agreement, the initial gains for European stock markets turned into drops near -0.5%. Negotiations on microchips, pharma produ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.